Clinical Trial Update: Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects [Phase 2]

View source ↗

Summary

The update announces termination of a Phase 2 trial evaluating lapatinib plus vinorelbine in ErbB2-overexpressing metastatic breast cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Tykerb) (lapatinib)
• Vinorelbine (Navelbine) (vinorelbine tartrate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: TERMINATED | Results posted: 2013-01-18